DigiM is a CRO focused on advancing development through microstructure understanding of the drug product and its intermediates. We partner with pharmaceutical companies to solve drug development challenges through the lens of microstructure analysis. Our digital transformation of product development has transformed approaches to formulation, process development, and dissolution assessment. Our image-based release simulation provides unprecedented performance prediction for controlled and long-acting dosage forms. DigiM partners with leading pharmaceutical innovators and regulatory agencies, delivering critical insight to advance development and formulation decisions.